Document 0318
 DOCN  M9550318
 TI    [Differences in the cellular response of the immune system in patients
       with Paget's disease of bone after elcatonin and etidronate
       administration]
 DT    9505
 AU    Rapado A; Lopez Gavilanes E; Palomino P; Yague M; de la Piedra C; Diaz
       Curiel M; Ortiz F; Servicio de Medicina Interna (Unidad Metabolica),
       Fundacion; Jimenez Diaz y Universidad Autonoma, Madrid.
 SO    Rev Clin Esp. 1994 Nov;194(11):970-3. Unique Identifier : AIDSLINE
       MED/95148941
 AB    A cellular immunological defect is present in patients with Paget's
       disease of the bone. Low counts of CD4, high counts of CD8, and a low
       CD4/CD8 ratio were observed in 58 patients compared with controls. These
       findings were not correlated with the metabolic activity of the disease.
       After therapy with Elcatonine an improvement in the cellular
       immunological defect was observed in 15 patients. Etidronate improved
       the biochemical bone patterns but no changes were observed in the number
       of lymphocytic subpopulations. These changes can be related to the
       improvement in the bone metabolic disorder or be the result of an effect
       on the altered immunity in this disease.
 DE    Aged  Biological Markers/ANALYSIS  Bone Remodeling/DRUG EFFECTS
       Calcitonin/*ANALOGS & DERIVATIVES/ADMINISTRATION & DOSAGE  Comparative
       Study  CD4-CD8 Ratio/DRUG EFFECTS  Drug Evaluation  English Abstract
       Etidronate Disodium/*ADMINISTRATION & DOSAGE  Female  Human  Immune
       System/*DRUG EFFECTS/IMMUNOLOGY  Immunity, Cellular/DRUG EFFECTS  Male
       Middle Age  Osteitis Deformans/*DRUG THERAPY/*IMMUNOLOGY/METABOLISM
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).